Navigation Links
Spheris Reports Fourth Quarter and Year-End 2007 Results
Date:3/26/2008

TDA is a non-GAAP financial measure. Please refer to the "Supplemental Financial Information" and related note contained in this press release for further discussion and reconciliation of GAAP financial measures to EBITDA.

Financial Highlights - Year Ended December 31, 2007

Net revenues for the year ended December 31, 2007 were $200.4 million compared with $207.1 million in 2006. The decline in net revenues during 2007 as compared with 2006 was primarily caused by delayed implementations during the first half of 2007 of signed new business, industry pricing pressures affecting both our existing and new customer relationships and less signed new business driven, in part, by the timing of the Company's new technology development initiatives. Operating income was $7.4 million, or 3.7 % of net revenues, during 2007 compared with $4.1 million, or 2.0% of net revenues, during 2006. The improvement in operating income margin during 2007 was primarily due to operational cost savings from increased utilization of the Company's global production capabilities, lower MLS-related direct costs and other operating expense reductions, as well as decreased depreciation expense. These savings were partially offset by the impact of unfavorable foreign currency exchange rates associated with production costs of the Company's Indian operations.

EBITDA was $31.6 million, or 15.8% of net revenues, in the year ended December 31, 2007 compared with $30.7 million, or 14.8% of net revenues, in 2006. The increase in 2007 EBITDA as compared with 2006 was primarily due to the impacts of operating cost savings and decreased depreciation expense described above.

Commenting on the fourth quarter and year-end 2007 results, Steven E. Simpson, president and chief executive officer of Spheris, stated, "I'm pleased to announce that we not only finished the year with a strong annual EBITDA performance, but also with great confidence that the sound technology investments we've
'/>"/>

SOURCE Spheris
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Spheris Sets Fourth Quarter 2007 Earnings Release and Conference Call Dates
2. Spheris Elects New Board Member
3. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
4. QMed, Inc. Reports Year-End and Fourth Quarter Results
5. Pelosi Statement on Social Security and Medicare Trustees Reports
6. NASI Experts Available to Comment on 2008 Social Security and Medicare Trustees Reports
7. SPO Medical Reports 2007 Sales: Growth of 35% Compared to 2006
8. Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
9. U.S. Army Study Reports WoundStat(TM) is Most Effective
10. CryoCor Reports 2007 Results
11. IPC The Hospitalist Company Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...ubstantially higher rates of mental health problem...s from a systematic review and meta-analysis publi...or studies over the past four decades containing d...ess people, Seena Fazel and colleagues of the Univ...,684 homeless individuals based in the US, UK, mai...
(Date:12/2/2008)...mposium today hosted by Johns,Hopkins University...s presented,the latest research in brain plastici... into technology to improve lives. Henry Mahncke, ...e that cognitive intervention developed by,Posit ...s ability to,reorganize itself throughout life. ...
(Date:12/2/2008)... assault are unsettling; the Department of Justice...e victim of attempted or actual sexual assault dur...rs from two universities, including the University...are unaware of drug-facilitated sexual assault and...including leaving drinks unattended. , "These f...
(Date:12/2/2008)...rprise software and online services veteran is exp...ers of Yugma,s instant web conferencing solutions ... December 2, 2008 -- Yugma , the leading web conf...aborate instantly using the Internet, announced th... Officer. , , ,Vas has more than 20 years of exper...
Breaking Medicine News(10 mins):Health News:Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions 2Health News:MU researcher calls for increase in sexual assault awareness programs on college campuses 2Health News:MU researcher calls for increase in sexual assault awareness programs on college campuses 3Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 2Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 3
... dengue cases in the national capital civic author...k the menace//, including prosecuting people who c...v, deputy municipal health officer of Delhi said, ...ted of which six proved to be fatal. We have recei...
...ealthcare treatment meted to those suffering menta...udy has found.// An investigation of 8 million hea...s opened a can of worms. The study spanning 18 m... a propensity suffer other illness alongside, as c...
...re is a “crisis” over lack of donors at sperm bank...linics being totally out of stock//, women and cou...problem. In 1990s, the highest number of donors w...decreasing. To make it worse, last year a new law ...
... reduce the bio-terrorism threat of the Venezuelan...hers at the University of Texas Medical Branch at ...al step in the development of effective drug thera...litis (VEE) virus, which is a potential bio-terror...
Other Medicine News:Health News:Shortage of donors at sperm bank clinics 2Health News:A New drug Developed To Fight The Bio-Terrorism Threat Of VEE Virus 2
(Date:12/1/2008)...PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc...ncet , one of the world,s leading medical journals...n regulator, experimental compound tasimelteon (VE... entitled "Melatonin agonist tasimelteon (VEC-162)...o randomised controlled multicentre trials." Resul...
(Date:12/1/2008)...hatasia Treated With ENB-0040 at Children,s Hospit...MONTREAL, Dec. 1 Enobia Pharma, an...loping novel therapeutics for serious bone disorde...in its clinical program for hypophosphatasia was d...herapy (ERT) with ENB-0040 for the treatment of th...
(Date:12/1/2008)...December 1 Following a,...t to procure an MVA-based,third generation small...,Canada, on behalf of the Canadian Department of N...an Nordic for the delivery of IMVAMUNE(R). , ...R) as part of the,country,s bio-preparedness prog...
(Date:11/30/2008).... 1 Older adults who ex...w and a greater number of small blood vessels in t... the annual meeting of the Radiological Society of...ucted at the University of North Carolina ( UNC)...ns of older adults who exercise to brain scans of ...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Thyroid Hormone Could One Day Treat Osteoporosis 13954 1Thyroid Hormone Could One Day Treat Osteoporosis 13954 2Thyroid Hormone Could One Day Treat Osteoporosis 13954 3Alarming growth in expected CO2 emissions in China finds UC analysis 2451 1Alarming growth in expected CO2 emissions in China finds UC analysis 2451 2Alarming growth in expected CO2 emissions in China finds UC analysis 2451 3GFX 3A Wrinkle Killer or Botox 28R 29 Hit Man 3F 13950 1GFX 3A Wrinkle Killer or Botox 28R 29 Hit Man 3F 13950 2GFX 3A Wrinkle Killer or Botox 28R 29 Hit Man 3F 13950 3Injection of human umbilical cord blood helps the aging brain 13948 1Injection of human umbilical cord blood helps the aging brain 13948 2
...ay 29, 2007 - Gilead,Sciences, Inc. (Nasdaq:GILD) ...007) study of aztreonam lysine for inhalation for,...who have,pulmonary Pseudomonas aeruginosa (P. aeru...e at Day 28 from baseline in respiratory,symptoms,...Revised,(CFQ-R), a patient-reported outcome (PRO) ...
...for Organ Transplantation, HORSHOLM, Denmark, May ...a announces positive Phase I clinical results for,... Heads into US,Phase II clinical trials for organ ...:LCP) announces positive results,from its Phase I ..., once-daily tacrolimus tablet. , A series of Phas...
Other Medicine Technology:Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 2LifeCycle Pharma Announces Positive Phase I Clinical Results for,its Transplantation Product Candidate, LCP-Tacro 3
VERSASTEP™ Reposable Short Single-Use For use with VERSASTEP™ Short Reusable Cannula, Dilator.
VersaStep™ Reposable Sterilization Trays.
VERSASTEP™ Plus Long Instrument for applications in laparoscopic procedures., ,The VERSASTEP™ Plus Long Instrument with 150mm Working Length is a unique endoscopic entry device that has
...ade; Blunt Tip Trocar consists of a blunt obturato... , ,The valve body assembly contains an internal ... instruments are inserted or withdrawn. The Autosu...verters to allow insertion of instruments of diffe...
Medicine Products: